查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1983804

流感治疗药物市场：2026-2032年全球市场预测（依剂型、给药途径、药物类别、最终用户和分销管道划分）

Influenza Medication Market by Form, Route Of Administration, Drug Class, End User, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 186 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，流感治疗市场价值将达到 37.9 亿美元，到 2026 年将成长至 39.9 亿美元，到 2032 年将达到 54.9 亿美元，复合年增长率为 5.44%。

主要市场统计数据
基准年 2025 37.9亿美元
预计年份：2026年 39.9亿美元
预测年份 2032 54.9亿美元
复合年增长率 (%) 5.44%

本导言部分全面且策略性地概述了影响现代流感治疗决策的临床因素、剂量形式和操作挑战。

流感治疗领域的特点是临床创新迅速、监管预期不断变化以及医疗服务模式发生变革，这些因素共同重新定义了製药公司、保险公司和医疗服务提供者的策略重点。

对科学、供应链和护理路径的变化进行详细审查，这些变化正在重塑抗病毒治疗模式、获取模式和相关人员的优先事项。

流感领域正经历一场变革，这场变革的驱动力来自科学的进步、不断演进的诊疗路径以及对药品供应和配送韧性的重新重视。具有全新作用机制的新型抗病毒药物正在改变治疗模式，而对快速诊断和门诊治疗的重新重视也在重塑药物的处方和分发地点及方式。

本研究将详细检验2025 年价格调整带来的供应链趋势和筹资策略调整，并找出需要对治疗药物跨境采购和库存策略进行重组的因素。

2025年新关税政策的实施将显着增加跨境药品供应链和筹资策略的复杂性。关税调整加剧了国际采购的成本影响，促使生产商和经销商重新评估其生产基地、综合供应合约和本地库存策略，以维持服务水准并确保产品流通的稳定性。

将给药途径、製剂特性、药物类别差异、分销管道和最终用户路径与策略决策因素联繫起来的详细细分见解。

详细的细分观点揭示了每种给药途径、剂型、药物类别、分销管道和最终用户环境的独特临床、商业性和营运影响，这反过来又有助于制定产品定位和通路策略。

我们根据全面的区域观点製定打入市场策略，协调美洲、欧洲、中东和非洲以及亚太地区在监管、分销和临床实践方面的差异。

区域趋势持续对全球流感治疗市场的准入、监管和采用模式产生决定性影响，因此需要製定细緻入微的区域策略，使临床证据与分销能力和支付方期望相一致。

投资那些在研发、製造、数位化伙伴关係以及以通路为中心的商业化模式方面实现差异化的公司的策略行动和能力。

在流感治疗领域，企业行为和策略立场决定了药物发现、开发、生产和商业化整体的竞争动态。

为领导者提供可操作且优先考虑的建议，以协调临床差异化和供应弹性、通路优化以及基于证据的打入市场策略。

产业领导者应采取一系列切实可行的措施，将临床差异化、营运韧性和通路优化相结合，以创造价值并支持改善患者预后。

检验采用高度透明、以证据为基础的调查方法来验证我们的发现和建议，该方法结合了专家访谈、系统性的二手研究和情境检验验证。

本报告的调查方法结合了多方面的证据整合、与专家的对话以及系统性的检验，以得出可靠且可操作的结论。

一项果断的整合，强调在临床创新、供应弹性和通路策略方面的整合执行，以确保患者能够获得治疗并带来明显的益处。

总之，流感治疗生态系统正处于一个转折点，科学创新、通路演变和供应韧性相互交织，重新定义了整个价值链上相关人员的策略挑战。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章：流感治疗市场：以剂型划分

  • 注射药物
  • 吸入用粉末
  • 悬浮液
  • 药片
    • 金刚烷胺
    • 巴洛沙韦酯
    • 奥司他韦
    • 金刚烷胺

第九章：流感治疗市场：依给药途径划分

  • 吸入
  • 静脉
  • 口服
    • 悬浮液
    • 药片

第十章：流感治疗市场：依药物类别划分

  • 核酸内切酶抑制剂
  • M2离子通道抑制剂
    • 金刚烷胺
    • 金刚烷胺
  • 神经氨酸酶抑制剂
    • 奥司他韦
    • 帕拉米韦
    • 扎那米韦

第十一章 流感治疗市场：依最终使用者划分

  • 居家医疗
  • 医院
  • 门诊部

第十二章：流感治疗市场：依通路划分

  • 医院药房
  • 网路药房
  • 零售药房

第十三章：流感治疗市场：依地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章 流感治疗市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十五章 流感治疗市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章：美国流感治疗市场

第十七章：中国流感治疗市场

第十八章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Abbott Laboratories
  • Agilent Technologies, Inc.
  • AstraZeneca PLC
  • Bio-Rad Laboratories, Inc.
  • Bristol-Myers Squibb Company
  • Cocrystal Pharma, Inc.
  • CSL Limited
  • Daiichi Sankyo Company, Limited
  • Eli Lilly and Company
  • F. Hoffmann-La Roche AG
  • GlaxoSmithKline PLC
  • Lupin Limited
  • Merck & Co., Inc.
  • NATCO Pharma Limited
  • Novartis AG
  • Pfizer Inc.
  • Qiagen NV
  • Sandoz International GmbH
  • Sanofi SA
  • Shionogi & Co., Ltd.
  • Sun Pharmaceutical Industries Ltd.
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.
  • Zydus Pharmaceuticals, Inc.
Product Code: MRR-F6513A06BE18

The Influenza Medication Market was valued at USD 3.79 billion in 2025 and is projected to grow to USD 3.99 billion in 2026, with a CAGR of 5.44%, reaching USD 5.49 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 3.79 billion
Estimated Year [2026] USD 3.99 billion
Forecast Year [2032] USD 5.49 billion
CAGR (%) 5.44%

A comprehensive and strategic introduction framing clinical drivers, delivery modalities, and operational imperatives that shape modern influenza therapeutic decision-making

The influenza therapeutic environment is characterized by rapid clinical innovation, evolving regulatory expectations, and shifting patterns of care delivery that together redefine strategic priorities for manufacturers, payers, and providers.

This summary synthesizes the current clinical imperatives-such as timely antiviral initiation, resistance monitoring, and outpatient management trends-alongside the operational realities that shape access and uptake. It highlights how advances in drug classes, delivery modalities, and distribution channels are intersecting with public health preparedness and seasonal demand variability. By placing clinical evidence, supply chain considerations, and stakeholder incentives in one coherent narrative, the introduction equips decision-makers with a holistic vantage point from which to assess risk, prioritize investment, and refine go-to-market planning.

Throughout the report, emphasis is placed on translating clinical differentiation into operational levers: formulary positioning, hospital stocking protocols, and outpatient prescribing workflows. The interplay between pharmacological attributes and channel capabilities is explored to identify friction points and opportunities for adoption. Ultimately, this introduction lays the foundation for a structured exploration of transformative shifts, tariff impacts, segmentation realities, regional dynamics, competitive behaviors, and practical recommendations that follow.

An in-depth review of scientific, supply chain, and care pathway shifts that are reshaping antiviral treatment patterns, access models, and stakeholder priorities

The influenza landscape is undergoing transformative shifts driven by scientific advances, care pathway evolution, and a renewed focus on resilience in supply and delivery. Emerging antiviral classes with novel mechanisms of action are changing treatment paradigms, while the renewed emphasis on rapid diagnostics and outpatient care is reshaping where and how therapies are prescribed and dispensed.

Concurrently, manufacturing agility and strategic sourcing have moved to the forefront as organizations seek to mitigate disruption risks. The convergence of improved inhalation and oral formulations, coupled with targeted molecular therapies, is prompting payers and providers to reassess treatment algorithms. As a result, stakeholders are increasingly prioritizing real-world effectiveness and resistance profiles over traditional efficacy endpoints, thereby influencing formulary decisions and clinical guidelines.

Additionally, digital health enablers and evolving distribution channels are facilitating more patient-centric models of care. Remote consultations, pharmacy home delivery services, and integrated care pathways support earlier initiation of therapy, which can materially affect demand patterns and stock management. Taken together, these shifts require companies to adopt integrated commercialization approaches that align R&D pipelines, regulatory strategies, and channel engagement to capture and sustain clinical and market relevance.

A detailed examination of 2025 tariff-driven supply chain dynamics and procurement adaptations that are reshaping cross-border sourcing and inventory strategies for therapeutics

The introduction of new tariff policies in 2025 has introduced material complexity into cross-border pharmaceutical supply chains and procurement strategies. Tariff adjustments have amplified the cost implications of international sourcing, prompting manufacturers and distributors to reassess production footprints, aggregate supply agreements, and local inventory strategies in order to preserve service levels and maintain predictable product flows.

In response, some organizations have accelerated localization of critical manufacturing steps or qualified alternate suppliers to reduce exposure to tariff volatility. Others have renegotiated commercial terms with downstream partners to distribute incremental costs more equitably across the value chain. These adaptations have emphasized the importance of flexible contracting, dual-sourcing, and inventory buffers to absorb tariff-induced cost movements without disrupting clinical availability.

Moreover, procurement teams and policy stakeholders are re-evaluating tender and purchasing frameworks to reflect new landed-cost realities. The practical consequence for market participants is a heightened emphasis on scenario planning and stress testing for international logistics, as well as a renewed focus on regulatory harmonization that can simplify cross-border movement of finished dosage forms and APIs. Ultimately, the tariff landscape has underscored the strategic value of supply chain resilience as an integral component of commercial planning.

Detailed segmentation insights connecting route of administration, formulation nuances, drug class differentiation, distribution channels, and end-user pathways to strategic decision levers

A granular segmentation lens reveals distinctive clinical, commercial, and operational implications across routes, forms, drug classes, distribution channels, and end-user settings that collectively inform product positioning and channel strategy.

When evaluating Route Of Administration, stakeholders must consider Inhalation as a modality that supports rapid pulmonary delivery for targeted effect, Intravenous as a critical option for severe cases and inpatient settings, and Oral treatments that cater to outpatient convenience; within Oral, the differentiation between Suspension and Tablet formulations affects adherence, pediatric dosing, and dispensing workflows. In terms of Form, Injection remains central to hospitalized care pathways while Powder Inhaler supports ambulatory administration; Suspension formulations enable flexible dosing for children and patients with swallowing difficulties, and Tablet formats encompass a portfolio that includes Amantadine, Baloxavir Marboxil, Oseltamivir, and Rimantadine with important implications for prescribing preferences and stock management.

From a Drug Class perspective, Endonuclease Inhibitors represent a newer mechanism with implications for resistance management and combination strategies; M2 Ion Channel Inhibitors encompass Amantadine and Rimantadine and carry a specific historical resistance and safety profile that limits their contemporary use in certain contexts; Neuraminidase Inhibitors include Oseltamivir, Peramivir, and Zanamivir and remain a cornerstone of current antiviral toolkits, particularly where early administration is feasible. Distribution Channel analysis highlights Hospital Pharmacy as the fulcrum for inpatient care and emergency treatment, Online Pharmacy as an accelerating conduit for direct-to-patient access and convenience, and Retail Pharmacy as the primary patient-facing touchpoint for seasonal demand and pharmacist-led counseling. Lastly, End User segmentation underscores that Home Care is increasingly important for early treatment initiation and adherence support, Hospitals represent acute care and severe case management, and Outpatient Clinics serve as critical points for diagnosis, initiation of therapy, and follow-up-each setting shaping stocking decisions, packaging choices, and patient education needs.

Taken together, these interlocking segmentation dimensions guide commercialization choices, from packaging and dispensing formats to channel partnerships and targeted medical affairs programs, and should be considered holistically when designing launch and lifecycle strategies.

Comprehensive regional perspective that aligns regulatory, distribution, and clinical practice differences across the Americas, Europe Middle East & Africa, and Asia-Pacific to inform market entry strategies

Regional dynamics continue to exert a defining influence on access, regulation, and adoption patterns across the global influenza therapeutic landscape, requiring nuanced regional strategies that align clinical evidence with distribution capabilities and payer expectations.

In the Americas, established outpatient infrastructures, integrated retail pharmacy networks, and strong home-care services create opportunities for orally administered antivirals and pharmacy-led initiation pathways; diagnostic availability and payer coverage models further shape adoption dynamics. In Europe, Middle East & Africa, variable regulatory pathways and heterogeneous reimbursement systems necessitate flexible launch approaches that account for national formularies and local clinical guidelines, while some markets in the region are investing in expanded inpatient capacities and supply chain modernization to strengthen pandemic preparedness. In the Asia-Pacific region, fast-moving adoption of digital health tools, rising investments in local manufacturing, and a high prevalence of community-based care models support diversified distribution strategies that can emphasize both inhalation and oral solution access depending on local prescribing habits.

Across all regions, stakeholders should calibrate product positioning to reflect differences in diagnostic infrastructure, pharmacist scope of practice, and payer arrangements. Moreover, regional policy initiatives focused on antimicrobial stewardship and resistance surveillance are increasingly shaping therapeutic choice and formulary decisions. Consequently, a regionally adaptive approach-one that aligns clinical messaging, supply strategies, and channel engagement with local system realities-will be essential for sustained access and uptake.

Strategic company behaviors and capability investments that are driving differentiation across R&D, manufacturing, digital partnerships, and channel-focused commercialization models

Company behaviors and strategic postures are defining competitive dynamics across discovery, development, manufacturing, and commercialization activities in the influenza therapeutics arena.

Leading firms are prioritizing portfolios that balance near-term commercial opportunities with longer-term investments in novel mechanisms and combination therapies. Strategic partnerships between biologics developers, specialty manufacturers, and diagnostic providers are accelerating integrated value propositions that tie antiviral therapies to rapid point-of-care testing and patient triage services. On the manufacturing front, firms are investing in modular and multi-site production capabilities to enhance flexibility and reduce single-source vulnerabilities, while quality and supply continuity programs are being elevated to board-level attention.

Commercially, companies are refining segmentation-driven go-to-market models that tailor messaging to hospital formulary committees, retail pharmacy networks, and digital health platforms. Medical affairs teams are increasingly central to lifecycle management, providing evidence generation and real-world outcomes studies that support positioning in the face of resistance concerns and comparative effectiveness questions. Some organizations are also exploring differentiated packaging, patient support solutions, and adherence technologies to strengthen outpatient persistence and therapeutic value. Collectively, these company-scale actions are reshaping competitive advantage from purely product-centric differentiation toward integrated solutions that span diagnostics, supply robustness, and channel-enabled patient access.

Actionable and prioritized recommendations for leaders to align clinical differentiation with supply resilience, channel optimization, and evidence-driven market access strategies

Industry leaders should adopt a set of pragmatic, actionable moves that align clinical differentiation with operational resilience and channel optimization to capture value and support improved patient outcomes.

First, embed resistance surveillance and real-world effectiveness endpoints into development and post-launch evidence plans so that therapeutic positioning responds to evolving clinical practice. Second, pursue supply chain diversification and local qualification of key suppliers to minimize exposure to tariff and logistics shocks; dual-sourcing and contingency inventories should be part of scenario planning. Third, design packaging and dosing formats that reflect end-user needs across home care, hospitals, and outpatient clinics, ensuring that pediatric and geriatric usability considerations are prioritized. Fourth, cultivate partnerships with diagnostic providers and digital platforms to accelerate timely initiation of therapy and to create bundled care pathways that improve adherence and outcomes. Fifth, tailor regional market access strategies to local reimbursement frameworks, aligning clinical dossiers with payer evidence requirements and engaging early with health technology assessment bodies when applicable.

Finally, invest in targeted commercial capabilities-such as pharmacy engagement teams, digital patient support, and outcome-based contracting expertise-that can translate clinical value into formulary acceptance and sustained uptake. By implementing these recommendations, leaders can minimize operational risk while enhancing the clinical and commercial performance of influenza therapeutics.

A transparent, evidence-driven methodology integrating primary expert interviews, systematic secondary research, and scenario triangulation to validate findings and recommendations

The research methodology underpinning this report combines multi-source evidence synthesis, expert engagement, and systematic validation to ensure robust and actionable conclusions.

Primary research included in-depth interviews with clinicians, pharmacy directors, supply chain executives, and payer representatives to ground interpretations of clinical practice, formulary behavior, and procurement dynamics. Secondary research involved systematic review of peer-reviewed clinical literature, regulatory guidance documents, public health advisories, and product labeling to corroborate mechanism-of-action insights and safety profiles. The analysis also integrated operational data on distribution channels and care settings to link clinical attributes with real-world execution challenges.

Findings were triangulated through cross-functional workshops and sensitivity analysis to test assumptions and surface alternative scenarios. Where uncertainties existed-such as evolving resistance trends or policy shifts-clear caveats were included and methodological choices were documented to support transparency. The result is a methodological approach that prioritizes evidence-backed interpretation, stakeholder validation, and scenario-aware recommendations to inform both near-term tactical choices and longer-term strategic planning.

A conclusive synthesis emphasizing integrated execution across clinical innovation, supply resilience, and channel strategies to secure access and demonstrable patient benefit

In conclusion, the influenza therapeutic ecosystem is at an inflection point where scientific innovation, channel evolution, and supply resilience converge to redefine strategic imperatives for stakeholders across the value chain.

The synthesis presented here underscores that successful programs will marry clinical differentiation with operational foresight: aligning novel mechanisms and user-friendly formulations with robust distribution strategies and evidence-generation plans. Regional nuances and tariff-driven supply pressures add layers of complexity that necessitate adaptive manufacturing footprints and close collaboration with payers and providers. Companies that proactively integrate diagnostic partnerships, strengthen pharmacy engagement, and prioritize real-world evidence generation will be better positioned to demonstrate value and secure sustainable access in diverse care settings.

Ultimately, the path forward is one of integrated execution-where R&D choices, commercial models, and supply chain strategies are orchestrated to accelerate timely access, manage resistance risk, and deliver measurable benefits for patients and health systems alike.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Influenza Medication Market, by Form

  • 8.1. Injection
  • 8.2. Powder Inhaler
  • 8.3. Suspension
  • 8.4. Tablet
    • 8.4.1. Amantadine
    • 8.4.2. Baloxavir Marboxil
    • 8.4.3. Oseltamivir
    • 8.4.4. Rimantadine

9. Influenza Medication Market, by Route Of Administration

  • 9.1. Inhalation
  • 9.2. Intravenous
  • 9.3. Oral
    • 9.3.1. Suspension
    • 9.3.2. Tablet

10. Influenza Medication Market, by Drug Class

  • 10.1. Endonuclease Inhibitors
  • 10.2. M2 Ion Channel Inhibitors
    • 10.2.1. Amantadine
    • 10.2.2. Rimantadine
  • 10.3. Neuraminidase Inhibitors
    • 10.3.1. Oseltamivir
    • 10.3.2. Peramivir
    • 10.3.3. Zanamivir

11. Influenza Medication Market, by End User

  • 11.1. Home Care
  • 11.2. Hospitals
  • 11.3. Outpatient Clinics

12. Influenza Medication Market, by Distribution Channel

  • 12.1. Hospital Pharmacy
  • 12.2. Online Pharmacy
  • 12.3. Retail Pharmacy

13. Influenza Medication Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Influenza Medication Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Influenza Medication Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Influenza Medication Market

17. China Influenza Medication Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Abbott Laboratories
  • 18.6. Agilent Technologies, Inc.
  • 18.7. AstraZeneca PLC
  • 18.8. Bio-Rad Laboratories, Inc.
  • 18.9. Bristol-Myers Squibb Company
  • 18.10. Cocrystal Pharma, Inc.
  • 18.11. CSL Limited
  • 18.12. Daiichi Sankyo Company, Limited
  • 18.13. Eli Lilly and Company
  • 18.14. F. Hoffmann-La Roche AG
  • 18.15. GlaxoSmithKline PLC
  • 18.16. Lupin Limited
  • 18.17. Merck & Co., Inc.
  • 18.18. NATCO Pharma Limited
  • 18.19. Novartis AG
  • 18.20. Pfizer Inc.
  • 18.21. Qiagen N.V.
  • 18.22. Sandoz International GmbH
  • 18.23. Sanofi SA
  • 18.24. Shionogi & Co., Ltd.
  • 18.25. Sun Pharmaceutical Industries Ltd.
  • 18.26. Takeda Pharmaceutical Company Limited
  • 18.27. Teva Pharmaceutical Industries Ltd.
  • 18.28. Viatris Inc.
  • 18.29. Zydus Pharmaceuticals, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL INFLUENZA MEDICATION MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL INFLUENZA MEDICATION MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL INFLUENZA MEDICATION MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY FORM, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES INFLUENZA MEDICATION MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA INFLUENZA MEDICATION MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL INFLUENZA MEDICATION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY INJECTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY INJECTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY INJECTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY POWDER INHALER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY POWDER INHALER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY POWDER INHALER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY SUSPENSION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY SUSPENSION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY SUSPENSION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY TABLET, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY TABLET, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY TABLET, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY TABLET, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY AMANTADINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY AMANTADINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY AMANTADINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY BALOXAVIR MARBOXIL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY BALOXAVIR MARBOXIL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY BALOXAVIR MARBOXIL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY OSELTAMIVIR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY OSELTAMIVIR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY OSELTAMIVIR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY RIMANTADINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY RIMANTADINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY RIMANTADINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY INHALATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY INHALATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY INHALATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY SUSPENSION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY SUSPENSION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY SUSPENSION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY TABLET, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY TABLET, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY TABLET, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY ENDONUCLEASE INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY ENDONUCLEASE INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY ENDONUCLEASE INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY M2 ION CHANNEL INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY M2 ION CHANNEL INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY M2 ION CHANNEL INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY M2 ION CHANNEL INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY AMANTADINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY AMANTADINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY AMANTADINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY RIMANTADINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY RIMANTADINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY RIMANTADINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY NEURAMINIDASE INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY NEURAMINIDASE INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY NEURAMINIDASE INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY NEURAMINIDASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY OSELTAMIVIR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY OSELTAMIVIR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY OSELTAMIVIR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY PERAMIVIR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY PERAMIVIR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY PERAMIVIR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY ZANAMIVIR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY ZANAMIVIR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY ZANAMIVIR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY HOME CARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY HOME CARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY HOME CARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY OUTPATIENT CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY OUTPATIENT CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY OUTPATIENT CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 93. AMERICAS INFLUENZA MEDICATION MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 94. AMERICAS INFLUENZA MEDICATION MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 95. AMERICAS INFLUENZA MEDICATION MARKET SIZE, BY TABLET, 2018-2032 (USD MILLION)
  • TABLE 96. AMERICAS INFLUENZA MEDICATION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 97. AMERICAS INFLUENZA MEDICATION MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 98. AMERICAS INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 99. AMERICAS INFLUENZA MEDICATION MARKET SIZE, BY M2 ION CHANNEL INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 100. AMERICAS INFLUENZA MEDICATION MARKET SIZE, BY NEURAMINIDASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 101. AMERICAS INFLUENZA MEDICATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 102. AMERICAS INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 103. NORTH AMERICA INFLUENZA MEDICATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 104. NORTH AMERICA INFLUENZA MEDICATION MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 105. NORTH AMERICA INFLUENZA MEDICATION MARKET SIZE, BY TABLET, 2018-2032 (USD MILLION)
  • TABLE 106. NORTH AMERICA INFLUENZA MEDICATION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 107. NORTH AMERICA INFLUENZA MEDICATION MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 108. NORTH AMERICA INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 109. NORTH AMERICA INFLUENZA MEDICATION MARKET SIZE, BY M2 ION CHANNEL INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 110. NORTH AMERICA INFLUENZA MEDICATION MARKET SIZE, BY NEURAMINIDASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 111. NORTH AMERICA INFLUENZA MEDICATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 112. NORTH AMERICA INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 113. LATIN AMERICA INFLUENZA MEDICATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 114. LATIN AMERICA INFLUENZA MEDICATION MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 115. LATIN AMERICA INFLUENZA MEDICATION MARKET SIZE, BY TABLET, 2018-2032 (USD MILLION)
  • TABLE 116. LATIN AMERICA INFLUENZA MEDICATION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 117. LATIN AMERICA INFLUENZA MEDICATION MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 118. LATIN AMERICA INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 119. LATIN AMERICA INFLUENZA MEDICATION MARKET SIZE, BY M2 ION CHANNEL INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 120. LATIN AMERICA INFLUENZA MEDICATION MARKET SIZE, BY NEURAMINIDASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 121. LATIN AMERICA INFLUENZA MEDICATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 122. LATIN AMERICA INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 123. EUROPE, MIDDLE EAST & AFRICA INFLUENZA MEDICATION MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPE, MIDDLE EAST & AFRICA INFLUENZA MEDICATION MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPE, MIDDLE EAST & AFRICA INFLUENZA MEDICATION MARKET SIZE, BY TABLET, 2018-2032 (USD MILLION)
  • TABLE 126. EUROPE, MIDDLE EAST & AFRICA INFLUENZA MEDICATION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 127. EUROPE, MIDDLE EAST & AFRICA INFLUENZA MEDICATION MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 128. EUROPE, MIDDLE EAST & AFRICA INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 129. EUROPE, MIDDLE EAST & AFRICA INFLUENZA MEDICATION MARKET SIZE, BY M2 ION CHANNEL INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 130. EUROPE, MIDDLE EAST & AFRICA INFLUENZA MEDICATION MARKET SIZE, BY NEURAMINIDASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 131. EUROPE, MIDDLE EAST & AFRICA INFLUENZA MEDICATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 132. EUROPE, MIDDLE EAST & AFRICA INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 133. EUROPE INFLUENZA MEDICATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 134. EUROPE INFLUENZA MEDICATION MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 135. EUROPE INFLUENZA MEDICATION MARKET SIZE, BY TABLET, 2018-2032 (USD MILLION)
  • TABLE 136. EUROPE INFLUENZA MEDICATION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 137. EUROPE INFLUENZA MEDICATION MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 138. EUROPE INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPE INFLUENZA MEDICATION MARKET SIZE, BY M2 ION CHANNEL INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPE INFLUENZA MEDICATION MARKET SIZE, BY NEURAMINIDASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 141. EUROPE INFLUENZA MEDICATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPE INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 143. MIDDLE EAST INFLUENZA MEDICATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 144. MIDDLE EAST INFLUENZA MEDICATION MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 145. MIDDLE EAST INFLUENZA MEDICATION MARKET SIZE, BY TABLET, 2018-2032 (USD MILLION)
  • TABLE 146. MIDDLE EAST INFLUENZA MEDICATION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 147. MIDDLE EAST INFLUENZA MEDICATION MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 148. MIDDLE EAST INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 149. MIDDLE EAST INFLUENZA MEDICATION MARKET SIZE, BY M2 ION CHANNEL INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 150. MIDDLE EAST INFLUENZA MEDICATION MARKET SIZE, BY NEURAMINIDASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 151. MIDDLE EAST INFLUENZA MEDICATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 152. MIDDLE EAST INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 153. AFRICA INFLUENZA MEDICATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 154. AFRICA INFLUENZA MEDICATION MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 155. AFRICA INFLUENZA MEDICATION MARKET SIZE, BY TABLET, 2018-2032 (USD MILLION)
  • TABLE 156. AFRICA INFLUENZA MEDICATION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 157. AFRICA INFLUENZA MEDICATION MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 158. AFRICA INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 159. AFRICA INFLUENZA MEDICATION MARKET SIZE, BY M2 ION CHANNEL INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 160. AFRICA INFLUENZA MEDICATION MARKET SIZE, BY NEURAMINIDASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 161. AFRICA INFLUENZA MEDICATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 162. AFRICA INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 163. ASIA-PACIFIC INFLUENZA MEDICATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 164. ASIA-PACIFIC INFLUENZA MEDICATION MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 165. ASIA-PACIFIC INFLUENZA MEDICATION MARKET SIZE, BY TABLET, 2018-2032 (USD MILLION)
  • TABLE 166. ASIA-PACIFIC INFLUENZA MEDICATION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 167. ASIA-PACIFIC INFLUENZA MEDICATION MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 168. ASIA-PACIFIC INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 169. ASIA-PACIFIC INFLUENZA MEDICATION MARKET SIZE, BY M2 ION CHANNEL INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 170. ASIA-PACIFIC INFLUENZA MEDICATION MARKET SIZE, BY NEURAMINIDASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 171. ASIA-PACIFIC INFLUENZA MEDICATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 172. ASIA-PACIFIC INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 173. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 174. ASEAN INFLUENZA MEDICATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 175. ASEAN INFLUENZA MEDICATION MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 176. ASEAN INFLUENZA MEDICATION MARKET SIZE, BY TABLET, 2018-2032 (USD MILLION)
  • TABLE 177. ASEAN INFLUENZA MEDICATION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 178. ASEAN INFLUENZA MEDICATION MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 179. ASEAN INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 180. ASEAN INFLUENZA MEDICATION MARKET SIZE, BY M2 ION CHANNEL INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 181. ASEAN INFLUENZA MEDICATION MARKET SIZE, BY NEURAMINIDASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 182. ASEAN INFLUENZA MEDICATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 183. ASEAN INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 184. GCC INFLUENZA MEDICATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 185. GCC INFLUENZA MEDICATION MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 186. GCC INFLUENZA MEDICATION MARKET SIZE, BY TABLET, 2018-2032 (USD MILLION)
  • TABLE 187. GCC INFLUENZA MEDICATION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 188. GCC INFLUENZA MEDICATION MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 189. GCC INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 190. GCC INFLUENZA MEDICATION MARKET SIZE, BY M2 ION CHANNEL INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 191. GCC INFLUENZA MEDICATION MARKET SIZE, BY NEURAMINIDASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 192. GCC INFLUENZA MEDICATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 193. GCC INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 194. EUROPEAN UNION INFLUENZA MEDICATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 195. EUROPEAN UNION INFLUENZA MEDICATION MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 196. EUROPEAN UNION INFLUENZA MEDICATION MARKET SIZE, BY TABLET, 2018-2032 (USD MILLION)
  • TABLE 197. EUROPEAN UNION INFLUENZA MEDICATION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 198. EUROPEAN UNION INFLUENZA MEDICATION MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 199. EUROPEAN UNION INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 200. EUROPEAN UNION INFLUENZA MEDICATION MARKET SIZE, BY M2 ION CHANNEL INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 201. EUROPEAN UNION INFLUENZA MEDICATION MARKET SIZE, BY NEURAMINIDASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 202. EUROPEAN UNION INFLUENZA MEDICATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 203. EUROPEAN UNION INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 204. BRICS INFLUENZA MEDICATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 205. BRICS INFLUENZA MEDICATION MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 206. BRICS INFLUENZA MEDICATION MARKET SIZE, BY TABLET, 2018-2032 (USD MILLION)
  • TABLE 207. BRICS INFLUENZA MEDICATION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 208. BRICS INFLUENZA MEDICATION MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 209. BRICS INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 210. BRICS INFLUENZA MEDICATION MARKET SIZE, BY M2 ION CHANNEL INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 211. BRICS INFLUENZA MEDICATION MARKET SIZE, BY NEURAMINIDASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 212. BRICS INFLUENZA MEDICATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 213. BRICS INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 214. G7 INFLUENZA MEDICATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 215. G7 INFLUENZA MEDICATION MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 216. G7 INFLUENZA MEDICATION MARKET SIZE, BY TABLET, 2018-2032 (USD MILLION)
  • TABLE 217. G7 INFLUENZA MEDICATION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 218. G7 INFLUENZA MEDICATION MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 219. G7 INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 220. G7 INFLUENZA MEDICATION MARKET SIZE, BY M2 ION CHANNEL INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 221. G7 INFLUENZA MEDICATION MARKET SIZE, BY NEURAMINIDASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 222. G7 INFLUENZA MEDICATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 223. G7 INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 224. NATO INFLUENZA MEDICATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 225. NATO INFLUENZA MEDICATION MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 226. NATO INFLUENZA MEDICATION MARKET SIZE, BY TABLET, 2018-2032 (USD MILLION)
  • TABLE 227. NATO INFLUENZA MEDICATION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 228. NATO INFLUENZA MEDICATION MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 229. NATO INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 230. NATO INFLUENZA MEDICATION MARKET SIZE, BY M2 ION CHANNEL INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 231. NATO INFLUENZA MEDICATION MARKET SIZE, BY NEURAMINIDASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 232. NATO INFLUENZA MEDICATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 233. NATO INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 234. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 235. UNITED STATES INFLUENZA MEDICATION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 236. UNITED STATES INFLUENZA MEDICATION MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 237. UNITED STATES INFLUENZA MEDICATION MARKET SIZE, BY TABLET, 2018-2032 (USD MILLION)
  • TABLE 238. UNITED STATES INFLUENZA MEDICATION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 239. UNITED STATES INFLUENZA MEDICATION MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 240. UNITED STATES INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 241. UNITED STATES INFLUENZA MEDICATION MARKET SIZE, BY M2 ION CHANNEL INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 242. UNITED STATES INFLUENZA MEDICATION MARKET SIZE, BY NEURAMINIDASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 243. UNITED STATES INFLUENZA MEDICATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 244. UNITED STATES INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 245. CHINA INFLUENZA MEDICATION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 246. CHINA INFLUENZA MEDICATION MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 247. CHINA INFLUENZA MEDICATION MARKET SIZE, BY TABLET, 2018-2032 (USD MILLION)
  • TABLE 248. CHINA INFLUENZA MEDICATION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 249. CHINA INFLUENZA MEDICATION MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 250. CHINA INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 251. CHINA INFLUENZA MEDICATION MARKET SIZE, BY M2 ION CHANNEL INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 252. CHINA INFLUENZA MEDICATION MARKET SIZE, BY NEURAMINIDASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 253. CHINA INFLUENZA MEDICATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 254. CHINA INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)